Company intelligence / Profile preview

Bionorica

Neumarkt i.d.OPf., Bavaria, Germanybionorica.com ↗

Ownership: Private
Development stage: Commercial

Overview

Bionorica has a long track record of commercialized phytopharmaceuticals for respiratory, gynecological, urinary tract, and liver conditions. Its lead pipeline programs include a Phase III trial of an herbal extract for primary dysmenorrhea and a Phase III program for dronabinol oral solution targeting spasticity in MS. The company’s marketed products are supported by clinical research demonstrating efficacy and safety.[6][8]

Therapeutic areas: GastroenterologyPulmonologyWomen's HealthNeurologyInfectious Diseases
Modalities: Plant-based therapeutics (phytopharmaceuticals)Herbal extracts and standardized plant compounds[2][3][7]Synthetic cannabinoids (e.g., dronabinol)[8]
Industry: Biotech

Drug pipeline

16 assets

Imupret

15 more assets in the full pipeline.

Request access →

Partnerships

ReproCELL

Beyond the preview

Go deeper on Bionorica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bionorica.

Explore the full profile